Literature DB >> 20541538

Carbocyclic 6-benzylthioinosine analogues as subversive substrates of Toxoplasma gondii adenosine kinase: biological activities and selective toxicities.

Omar N Al Safarjalani1, Reem H Rais, Young Ah Kim, Chung K Chu, Fardos N M Naguib, Mahmoud H El Kouni.   

Abstract

Toxoplasma gondii adenosine kinase (EC 2.7.1.20) is the major route of adenosine metabolism in this parasite. The enzyme is significantly more active than any other enzyme of the purine salvage in T. gondii and has been established as a potential chemotherapeutic target for the treatment of toxoplasmosis. Several 6-benzylthioinosines have already been identified as subversive substrates of the T. gondii but not human adenosine kinase. Therefore, these compounds are preferentially metabolized to their respective nucleotides and become selectively toxic against the parasites but not its host. In the present study, we report the testing of the metabolism of several carbocyclic 6-benzylthioinosines, as well as their efficacy as anti-toxoplasmic agents in cell culture. All the carbocyclic 6-benzylthioinosine analogues were metabolized to their 5'-monophosphate derivatives, albeit to different degrees. These results indicate that these compounds are not only ligands but also substrates of T. gondii adenosine kinase. All the carbocyclic 6-benzylthioinosine analogues showed a selective anti-toxoplasmic effect against wild type parasites, but not mutants lacking adenosine kinase. These results indicate that the oxygen atom of the sugar is not critical for substrate binding. The efficacy of these compounds varied with the position and nature of the substitution on their phenyl ring. Moreover, none of these analogues exhibited host toxicity. The best compounds were carbocyclic 6-(p-methylbenzylthio)inosine (IC(50)=11.9 microM), carbocyclic 6-(p-methoxybenzylthio)inosine (IC(50)=12.1 microM), and carbocyclic 6-(p-methoxycarbonylbenzylthio)inosine (IC(50)=12.8 microM). These compounds have about a 1.5-fold better efficacy relative to their corresponding 6-benzylthioinosine analogues (Rais et al., Biochem Pharmacol 2005;69:1409-19 [29]). The results further confirm that T. gondii adenosine kinase is an excellent target for chemotherapy and that carbocyclic 6-benzylthioinosines are potential anti-toxoplasmic agents. Copyright (c) 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20541538      PMCID: PMC2923275          DOI: 10.1016/j.bcp.2010.06.001

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  34 in total

1.  Structure-activity relationships of carbocyclic 6-benzylthioinosine analogues as subversive substrates of Toxoplasma gondii adenosine kinase.

Authors:  Young Ah Kim; Ravindra K Rawal; Jakyung Yoo; Ashoke Sharon; Ashok K Jha; Chung K Chu; Reem H Rais; Omar N Al Safarjalani; Fardos N M Naguib; Mahmoud H El Kouni
Journal:  Bioorg Med Chem       Date:  2010-04-08       Impact factor: 3.641

2.  Structure-activity relationship for the binding of nucleoside ligands to adenosine kinase from Toxoplasma gondii.

Authors:  M H Iltzsch; S S Uber; K O Tankersley; M H el Kouni
Journal:  Biochem Pharmacol       Date:  1995-05-17       Impact factor: 5.858

3.  Toxoplasmosis in patients with cancer.

Authors:  D M Israelski; J S Remington
Journal:  Clin Infect Dis       Date:  1993-11       Impact factor: 9.079

Review 4.  Toxoplasmosis in pregnancy.

Authors:  S Y Wong; J S Remington
Journal:  Clin Infect Dis       Date:  1994-06       Impact factor: 9.079

5.  Synthesis, biological evaluation and molecular modeling studies of N6-benzyladenosine analogues as potential anti-toxoplasma agents.

Authors:  Young Ah Kim; Ashoke Sharon; Chung K Chu; Reem H Rais; Omar N Al Safarjalani; Fardos N M Naguib; Mahmoud H el Kouni
Journal:  Biochem Pharmacol       Date:  2007-01-21       Impact factor: 5.858

6.  6-Benzylthioinosine analogues as subversive substrate of Toxoplasma gondii adenosine kinase: activities and selective toxicities.

Authors:  Reem H Rais; Omar N Al Safarjalani; Vikas Yadav; Vincenzo Guarcello; Marion Kirk; Chung K Chu; Fardos N M Naguib; Mahmoud H el Kouni
Journal:  Biochem Pharmacol       Date:  2005-05-15       Impact factor: 5.858

7.  Structure-activity relationships of 7-deaza-6-benzylthioinosine analogues as ligands of Toxoplasma gondii adenosine kinase.

Authors:  Young Ah Kim; Ashoke Sharon; Chung K Chu; Reem H Rais; Omar N Al Safarjalani; Fardos N M Naguib; Mahmoud H el Kouni
Journal:  J Med Chem       Date:  2008-06-19       Impact factor: 7.446

8.  Synthesis, biological activity and molecular modeling of 6-benzylthioinosine analogues as subversive substrates of Toxoplasma gondii adenosine kinase.

Authors:  Vikas Yadav; Chung K Chu; Reem H Rais; Omar N Al Safarjalani; Vincenzo Guarcello; Fardos N M Naguib; Mahmoud H el Kouni
Journal:  J Med Chem       Date:  2004-04-08       Impact factor: 7.446

9.  Biology of Toxoplasma gondii.

Authors:  S Y Wong; J S Remington
Journal:  AIDS       Date:  1993-03       Impact factor: 4.177

Review 10.  Potential chemotherapeutic targets in the purine metabolism of parasites.

Authors:  Mahmoud H el Kouni
Journal:  Pharmacol Ther       Date:  2003-09       Impact factor: 12.310

View more
  5 in total

1.  Kinetic mechanism of Toxoplasma gondii adenosine kinase and the highly efficient utilization of adenosine.

Authors:  Fardos N M Naguib; Reem H Rais; Omar N Al Safarjalani; Mahmoud H el Kouni
Journal:  Comp Biochem Physiol B Biochem Mol Biol       Date:  2015-06-23       Impact factor: 2.231

Review 2.  Review of Experimental Compounds Demonstrating Anti-Toxoplasma Activity.

Authors:  Madalyn M McFarland; Sydney J Zach; Xiaofang Wang; Lakshmi-Prasad Potluri; Andrew J Neville; Jonathan L Vennerstrom; Paul H Davis
Journal:  Antimicrob Agents Chemother       Date:  2016-11-21       Impact factor: 5.191

Review 3.  Adenosine kinase: exploitation for therapeutic gain.

Authors:  Detlev Boison
Journal:  Pharmacol Rev       Date:  2013-04-16       Impact factor: 25.468

Review 4.  Targeting MYC Dependence by Metabolic Inhibitors in Cancer.

Authors:  Himalee S Sabnis; Ranganatha R Somasagara; Kevin D Bunting
Journal:  Genes (Basel)       Date:  2017-03-31       Impact factor: 4.096

5.  A Toxoplasma gondii Oxopurine Transporter Binds Nucleobases and Nucleosides Using Different Binding Modes.

Authors:  Gustavo D Campagnaro; Hamza A A Elati; Sofia Balaska; Maria Esther Martin Abril; Manal J Natto; Fabian Hulpia; Kelly Lee; Lilach Sheiner; Serge Van Calenbergh; Harry P de Koning
Journal:  Int J Mol Sci       Date:  2022-01-10       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.